Boston Scientific Corporation (NYSE:BSX) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Boston Scientific Corporation has received a consensus recommendation of "Buy" from twenty-six brokerages, with an average 12-month price objective of $117.50.
• The company reported quarterly earnings of $0.75 per share, exceeding analysts' estimates and showing a 22.8% year-over-year revenue growth to $5.06 billion.
• Insider trading activity includes recent sales by executives, leading to a total of 345,029 shares being sold worth approximately $35.98 million over the last quarter.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) has been assigned an average recommendation of "Buy" from the twenty-six brokerages that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and three have assigned a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $117.50.

A number of analysts recently weighed in on the stock. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Oppenheimer upped their price objective on shares of Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a research report on Thursday, July 24th. Finally, Raymond James Financial upped their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 24th.

Boston Scientific Stock Down 0.9%

Shares of Boston Scientific stock opened at $105.18 on Tuesday. The company has a fifty day moving average price of $104.18 and a 200 day moving average price of $102.12. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific has a twelve month low of $78.90 and a twelve month high of $108.94. The stock has a market cap of $155.85 billion, a price-to-earnings ratio of 62.61, a price-to-earnings-growth ratio of 2.56 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the prior year, the company earned $0.62 EPS. The firm's revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This represents a 58.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the company's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $18,347,824.96. This trade represents a 24.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 345,029 shares of company stock worth $35,976,603 over the last quarter. Company insiders own 0.50% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors have recently modified their holdings of the stock. HM Payson & Co. raised its stake in shares of Boston Scientific by 1.4% in the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after purchasing an additional 98 shares in the last quarter. Riverwater Partners LLC raised its stake in shares of Boston Scientific by 3.3% in the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider's stock valued at $333,000 after purchasing an additional 98 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management raised its stake in shares of Boston Scientific by 3.8% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider's stock valued at $291,000 after purchasing an additional 99 shares in the last quarter. Baldwin Investment Management LLC raised its stake in shares of Boston Scientific by 1.2% in the 4th quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock valued at $781,000 after purchasing an additional 102 shares in the last quarter. Finally, IVC Wealth Advisors LLC raised its stake in shares of Boston Scientific by 4.9% in the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider's stock valued at $236,000 after purchasing an additional 102 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.